Vimeo

News

AstraZeneca has agreed to sell some of the rights to its drugs Nexium and Vimovo to Grünenthal for an upfront payment of $922 million.

News

argenx's CD122 inhibitor FB102, added to its pipeline through the $2.2bn acquisition of Forte, is moving into phase 3 testing for coeliac disease.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.